A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months.
Dunachie
Susanna J
SJ
Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK. susie.dunachie@ndm.ox.ac.uk
Walther
Michael
M
Vuola
Jenni M
JM
Webster
Daniel P
DP
Keating
Sheila M
SM
Berthoud
Tamara
T
Andrews
Laura
L
Bejon
Philip
P
Poulton
Ian
I
Butcher
Geoffrey
G
Watkins
Katherine
K
Sinden
Robert E
RE
Leach
Amanda
A
Moris
Philippe
P
Tornieporth
Nadia
N
Schneider
Joerg
J
Dubovsky
Filip
F
Tierney
Eveline
E
Williams
Jack
J
Heppner
D Gray
DG
Gilbert
Sarah C
SC
Cohen
Joe
J
Hill
Adrian V S
AV
D000293:Adolescent; D000328:Adult; D000913:Antibodies, Protozoan / Q000097:blood; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000096:biosynthesis; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D014616:Vaccinia virus / Q000276:immunology*
D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; C493155:RTS,S-AS02A vaccine; D007371:Interferon-gamma